- Stocks
- Pharma & Healthcare
- Makers Labs
Makers Labs share price
NSE: MAKERSLPharma & HealthcareDrug Manufacturers - Specialty & Generic
Makers Labs at a glance
Makers Labs (NSE: MAKERSL) closed at ₹191.02 on 22 Oct 2026, down 3.53% on the day. With a market capitalisation of ₹113 Cr, it ranks 2594th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 48× trailing earnings, against a return on equity of 3.2% in FY26. Its 52-week range is ₹150.00 (19 Aug 2026) to ₹236.00 (25 Aug 2026); the last close is 19.1% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹36 Cr (+5.5% year on year) and net profit ₹4 Cr (+125.3%), on a consolidated basis. Promoters held 61.27% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹113 CrRank 2594 on NSE
- P/E (trailing)
- 48×
- Price to book
- 1.09×FY26
- EPS (TTM)
- ₹3.98to Q4 FY26
- ROE
- 3.2%FY26
- ROCE
- 9.0%FY26
- Debt to equity
- 0.07FY26
- Net profit margin
- 5.6%FY26
- Book value / share
- ₹123.59FY26
- 52-week high
- ₹236.0025 Aug 2026
- 52-week low
- ₹150.0019 Aug 2026
- RSI (14-day)
- 52.7
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −3.53% | −4.5% | +0.0% | — | — |
Makers Labs quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹30 Cr | ₹30 Cr | ₹28 Cr | ₹34 Cr | ₹35 Cr | ₹34 Cr | ₹36 Cr | ₹36 Cr |
| Revenue YoY | +18.3% | +18.0% | +4.5% | +21.9% | +18.3% | +15.6% | +28.8% | +5.5% |
| Net profit | −₹1 Cr | ₹10 Cr | ₹0 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹4 Cr |
| Net profit YoY | — | — | — | — | — | −92.3% | +740.7% | +125.3% |
| Net margin | −2.4% | 33.0% | 1.0% | 4.7% | 3.7% | 2.2% | 6.4% | 10.0% |
| EPS | −₹1.67 | ₹14.94 | ₹0.50 | ₹0.08 | ₹0.74 | −₹0.20 | ₹1.59 | ₹1.85 |
Makers Labs financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹69 Cr | ₹127 Cr | ₹101 Cr | ₹104 Cr | ₹121 Cr | — |
| Operating profit | ₹3 Cr | ₹16 Cr | −₹1 Cr | −₹4 Cr | ₹14 Cr | — |
| Net profit | ₹1 Cr | ₹12 Cr | −₹2 Cr | −₹5 Cr | ₹11 Cr | — |
| EPS (₹) | ₹3.00 | ₹10.00 | −₹8.00 | −₹11.00 | ₹13.00 | — |
| Cash from operations | ₹0 Cr | ₹9 Cr | −₹9 Cr | ₹1 Cr | −₹4 Cr | — |
| Total debt | ₹6 Cr | ₹3 Cr | ₹4 Cr | ₹9 Cr | ₹2 Cr | ₹1 Cr |
| Shareholders' equity | ₹54 Cr | ₹60 Cr | ₹69 Cr | ₹63 Cr | ₹71 Cr | ₹73 Cr |
Makers Labs shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 61.27% | 61.27% | 61.27% | 61.27% | 61.27% | 61.27% |
| Domestic institutions | 0.39% | 0.39% | 0.39% | 0.39% | 0.39% | 0.39% |
| Non-institutions | 38.34% | 38.34% | 38.34% | 38.34% | 38.34% | 38.34% |
Makers Labs vs peers
The listed Pharma & Healthcare companies nearest to Makers Labs by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| KREBSBIOKrebs Biochemicals and Industries | ₹56.59 | +0.78% | −19.3% | ₹122 Cr | — | — |
| GODAVARIGodavari Drugs | — | — | — | ₹120 Cr | — | — |
| PARNAXLABParnax Lab | ₹104.00 | −4.54% | — | ₹119 Cr | 10.1 | — |
| MAKERSLMakers Labs | ₹191.02 | −3.53% | — | ₹113 Cr | 48 | — |
| PHARMAIDPharmaids Pharm | — | — | — | ₹113 Cr | — | — |
| BALAXIBALAXI PHARMACEUTICALS | ₹20.31 | −4.65% | −52.7% | ₹112 Cr | 78.1 | — |
| ALPAAlpa Laboratories | ₹51.70 | +0.90% | −41.8% | ₹109 Cr | 7.3 | — |
Ask anything about Makers Labs
Pivot answers on the live chart with evidence you can check, and tests strategies against MAKERSL's own history. Try: “Why has MAKERSL moved over the last three months?” · “Backtest a 50-day moving-average crossover on MAKERSL over five years” · “Compare MAKERSL with KREBSBIO on margins and valuation”
Frequently asked questions about Makers Labs
What is the share price of Makers Labs today?
Makers Labs (NSE: MAKERSL) last closed at ₹191.02 on 22 Oct 2026. Its 52-week high is ₹236.00 and its 52-week low is ₹150.00.
What is the market cap of Makers Labs?
Makers Labs' market capitalisation is ₹113 Cr (₹113 Cr) at the 22 Oct 2026 close, ranking 2594th among the NSE companies Pivot tracks.
What is the P/E ratio of Makers Labs?
Makers Labs trades at a trailing P/E of 48. The median P/E of the 3 closest Pharma & Healthcare peers by market cap is 10.1.
What is the ROE and ROCE of Makers Labs?
Return on equity was 3.2% in FY26 and return on capital employed was 9.0% in FY26 (consolidated figures).
Is Makers Labs a debt-free company?
No. Makers Labs' debt-to-equity ratio was 0.07 in FY26, with total debt of ₹1 Cr.
What were Makers Labs' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Makers Labs reported revenue of ₹36 Cr, +5.5% year on year, and net profit of ₹4 Cr, +125.3% year on year.
What is the shareholding pattern of Makers Labs?
As of 30 Jun 2026: promoters 61.27%, domestic institutions 0.39%, non-institutions 38.34%.
Who are Makers Labs' competitors?
The listed Pharma & Healthcare companies closest to Makers Labs by market cap are Krebs Biochemicals and Industries, Godavari Drugs, Parnax Lab, Pharmaids Pharm, BALAXI PHARMACEUTICALS and Alpa Laboratories.
Is Makers Labs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Makers Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MAKERSL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with M · all NSE stocks · this page as text